拉罗替尼(Vitrakvi)中文说明书

Larotrectinib (larotrectinib) English trade name: Vitrakvi, is a potent, oral, selective tropomyosin receptor kinase (TRKs) inhibitor, acting on TRKB, TRKB, and TRKC kinases. Effectively targets up to 17 types of cancer. Larotrectinib was approved by the US FDA on November 26, 2018. Larotrectinib can be used in cancer patients with TRK fusion regardless of age and tumor type, and reports have proven that it can exert a durable anti-tumor effect and be well tolerated.

Larotrectinib is the first oral pan-cancer targeted drug that can be used by children and adults with NTRK gene fusions in different tumors. NTRK gene fusion is a rare cancer driver that is a chromosomal alteration that results in the production of abnormal TRK fusion proteins that are conformally activated. Regardless of the primary site of the tumor, these TRK fusion proteins can promote tumor spread and growth, leading to the formation of TRK fusion tumors. TRK fusion tumors are not limited to certain tissue types and can occur anywhere in the body. The incidence of TRK fusion tumors varies widely across a variety of adult and pediatric solid tumors, including lung, thyroid, gastrointestinal (colon, cholangiocarcinoma, pancreatic, and appendiceal), sarcomas, central nervous system (glioma and glioblastoma), salivary gland (mammary-like secretory carcinoma), and childhood cancers (infantile fibrosarcoma and soft tissue sarcoma). Therefore, larotrectinib is a "broad-spectrum" anticancer drug that can meet the clinical needs of patients with many different types of tumors.

Larotrectinib is a broad-spectrum anticancer drug that is effective against many different tumors. Types that can be effectively treated: 17 types of tumors including lung cancer, thyroid cancer, melanoma, gastrointestinal cancer, colon cancer, soft tissue sarcoma, salivary gland, infantile fibrosarcoma, appendiceal cancer, breast cancer, bile duct cancer, and pancreatic cancer.

The guidelines for taking larotrectinib include: (1) For adult or pediatric patients with a body surface area greater than 1㎡, the recommended dose is 100 mg twice a day, with or without food; (2) For pediatric patients with a body surface area less than 1㎡, the recommended dose is 100 mg/㎡ (calculated based on body surface area) each time, twice a day, with or without food.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: